Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal.
Justin Balko, PharmD, PhD
Advertisement
Articles by Justin Balko, PharmD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
2
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
3
Fifth Death Confirmed in NYC Legionnaires' Outbreak
4
Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape
5